What insider share transactions did ELDN president Steven Perrin report?

President Steven Perrin reported two transactions: a grant of 152,353 Common Stock shares from a retention bonus settlement and a withholding of 72,138 shares at $3.38 per share to cover tax obligations on the same date.

Was Steven Perrin’s ELDN share transaction part of a retention bonus?

Yes. The acquisition of 152,353 shares reflects settlement of a retention bonus award for Steven Perrin. The related agreement was entered into on April 27, 2023, and the shares were issued on 2026-07-31 as part of that compensation arrangement.

Eldon Pharmaceuticals president granted 152,353 shares

Q: How many Eledon Pharmaceuticals (ELDN) shares were granted to Steven Perrin?

Steven Perrin was granted 152,353 shares of Eledon Common Stock on 2026-07-31. These shares were issued upon settlement of a retention bonus award under an agreement originally entered into on April 27, 2023, and carried a reported price of $0.00.

Q: How many ELDN shares were withheld to pay Steven Perrin’s taxes?

A total of 72,138 Eledon Common Stock shares were withheld from Steven Perrin. The withholding occurred on 2026-07-31 at a value of $3.38 per share and was used to satisfy tax withholding obligations due on the retention bonus settlement date.

Q: Were Steven Perrin’s ELDN transactions reported as open-market buys or sells?

No. The filing shows a grant/award acquisition of 152,353 shares and a tax-withholding disposition of 72,138 shares. The disposition, coded “F,” represents shares withheld to pay tax liabilities, not an open-market purchase or sale.

Eledon Pharmaceuticals, Inc. reported that President Steven Perrin received 152,353 shares of Common Stock on 2026-07-31 upon settlement of a retention bonus award, under an agreement entered into on April 27, 2023.

Accepted by SEC EDGAR 08/04/2026 - 05:22 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Eledon Pharmaceuticals, Inc. reported that President Steven Perrin received 152,353 shares of Common Stock on 2026-07-31 upon settlement of a retention bonus award, under an agreement entered into on April 27, 2023. On the same date, 72,138 shares were withheld at $3.38 per share to satisfy tax withholding obligations.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Perrin Steven

Role President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	152,353	$0.00	$0.00
Tax Withholding	Common Stock ^F2	72,138	$3.38	$244K

Holdings After Transaction: Common Stock — 81,215 shares (Direct)

Footnotes (2)

F1. Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.
F2. Represents shares withheld to pay tax withholding obligations due on the date of settlement.

Key Figures

Retention bonus shares granted: 152,353 shares Shares withheld for taxes: 72,138 shares Tax withholding price: $3.38 per share

3 metrics

Retention bonus shares granted 152,353 shares Common Stock granted to Steven Perrin on 2026-07-31 upon settlement of a retention bonus award

Shares withheld for taxes 72,138 shares Common Stock withheld on 2026-07-31 to pay tax withholding obligations on the settlement date

Tax withholding price $3.38 per share Per-share value used for the tax-withholding disposition of 72,138 shares on 2026-07-31

Key Terms

retention bonus award, tax withholding obligations, withholding securities

3 terms

retention bonus award financial

"Represents shares issuable on settlement of a retention bonus award"

tax withholding obligations financial

"Represents shares withheld to pay tax withholding obligations due"

withholding securities financial

"Payment of tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Eledon Pharmaceuticals (ELDN) shares were granted to Steven Perrin?

Steven Perrin was granted 152,353 shares of Eledon Common Stock on 2026-07-31. These shares were issued upon settlement of a retention bonus award under an agreement originally entered into on April 27, 2023, and carried a reported price of $0.00.

How many ELDN shares were withheld to pay Steven Perrin’s taxes?

A total of 72,138 Eledon Common Stock shares were withheld from Steven Perrin. The withholding occurred on 2026-07-31 at a value of $3.38 per share and was used to satisfy tax withholding obligations due on the retention bonus settlement date.

Were Steven Perrin’s ELDN transactions reported as open-market buys or sells?

No. The filing shows a grant/award acquisition of 152,353 shares and a tax-withholding disposition of 72,138 shares. The disposition, coded “F,” represents shares withheld to pay tax liabilities, not an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perrin Steven

(Last)

(First)

(Middle)

C/O ELEDON PHARMACEUTICALS, INC.

19800 MACARTHUR BLVD STE. 250

(Street)

IRVINE

CALIFORNIA

92612

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eledon Pharmaceuticals, Inc. [ ELDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/31/2026		A⁽¹⁾		152,353	A	$0	153,353	D
Common Stock	07/31/2026		F⁽²⁾		72,138	D	$3.38	81,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares issuable on settlement of a retention bonus award granted to the Reporting Person. The retention bonus agreement was entered into on April 27, 2023.

2. Represents shares withheld to pay tax withholding obligations due on the date of settlement.

	/s/ Paul Little, as attorney-in-fact for Steven Perrin, Ph.D.	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR